about
Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapyImmune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice.Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells.Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control.Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway.The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cellsInterferons induce CXCR3-cognate chemokine production by human metastatic melanoma.CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes.Immunity to melanoma antigens: from self-tolerance to immunotherapy.CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profilesThe BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cellsDifferential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.CXCR3+ monocytes/macrophages are required for establishment of pulmonary metastasesThe mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.Adaptive immunity programmes in breast cancer.Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production.Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities.Tumor-induced immune dysfunction: the macrophage connection.Tumor growth modulates macrophage nitric oxide production following paclitaxel administration.Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.LNK suppresses interferon signaling in melanomaBeta-glucan-induced inflammatory monocytes mediate antitumor efficacy in the murine lungDistinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology
P50
Q30276126-A7564D55-2BBB-4940-AF9F-8A6CDBFBC32EQ30276128-D9BD1AC6-9D99-4DEB-B597-E27ECDF37A20Q30305530-754A77A1-62BD-4C36-AF5E-BB128B31C003Q30308174-FF1AE631-2644-4CFD-84E2-58F3BC1A3383Q30310231-2E897AB0-C191-42F9-82E4-9E35E1CC5858Q30310494-48A83276-C0ED-4A7A-89B5-AC3448FE6CB7Q30311891-1C2C78B1-1CBC-4109-B6ED-56B7FBF87026Q30409722-C416B673-E09D-4E9A-B11F-D8D36B807B33Q30412235-F6FF9EBD-4EAC-4045-9C12-4F20C4D1D9F5Q30427748-78FC2432-1B3B-46BB-BCDF-CF1FE2DEB127Q30429749-A4DAEB25-2A4F-4E0F-B7B4-201DF6567D4AQ30430002-DD1A7AF3-162E-4829-9B60-2D7501A55544Q30435000-16A7BE31-91DB-4144-A417-30BC4D629B9AQ30436882-7AF6765A-BCAA-47B2-83D7-7BD272FB9ED9Q30440039-4C544449-EF47-426B-A36D-EBFBFA371C82Q30440584-98DAF0F1-BDF9-4D81-9C33-A66B16ECA2A6Q35583851-04D2544F-9CFE-42DC-9D67-68FFED6F7E42Q36499105-FA03B7D2-2E62-46B7-ABA5-F3E2A99D23D2Q37308167-EEC1F0EF-5798-4845-A208-BC041382FAA6Q37394572-F1EA6981-383E-420C-80F0-A1FB3797E40AQ37705228-142B9A93-F195-499B-AE66-934DEFD37AFAQ37728730-EDAEE675-9C8F-44DF-BBB0-DF87068FA6B5Q38895406-37E786BA-6B0D-4973-9A40-041498F56179Q38937896-5A0F9300-EBFE-4AC5-95DA-01DF660A4A9CQ38996594-A44D986B-D3D4-41F5-A897-FB8B358EF18CQ40864107-D3DF46C1-990F-4FBA-9600-4A84648E18F6Q41078728-EBB64176-A3FE-46A0-AFC3-231FA393A23BQ43004346-36DD9E14-B3A1-4026-B2B2-BEF7BC4D949AQ45106591-557394B5-6587-4677-9FFD-9CE54BC0A114Q45107495-2D6011A5-7E39-4D39-BFE2-24475106D221Q45113707-AD290349-D0FE-411B-9DE8-39995828B1AEQ45115071-18384F29-909F-49A3-B5C3-83C1DD6207DDQ50535273-850C7B46-3533-4129-8C79-868FA8ADB33FQ64052024-3F201C70-F99C-404E-A3AF-DAFB893BB3BCQ91243790-449A4E84-8D18-4AAC-994A-2EA458237068Q91555544-CDFBA3D3-E205-4955-9A17-6E6876F13CF7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David W. Mullins
@ast
David W. Mullins
@en
David W. Mullins
@es
David W. Mullins
@nl
David W. Mullins
@sl
type
label
David W. Mullins
@ast
David W. Mullins
@en
David W. Mullins
@es
David W. Mullins
@nl
David W. Mullins
@sl
prefLabel
David W. Mullins
@ast
David W. Mullins
@en
David W. Mullins
@es
David W. Mullins
@nl
David W. Mullins
@sl
P106
P1153
7102599177
P21
P31
P496
0000-0002-2644-350X